Schwann cells for treatment of spinal cord injury

The aim of this study was to assess the safety of autologous human Schwann cells in treating spinal cord injury. Schwann cells harvested from the sural nerve are autologously transplanted, after a 3-5-week culture period, into the epicenter of the spinal cord injury to avoid immune rejection. No adverse events to transplantation were recorded.